Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?

Argenx posted Q2 revenue growth of +60% YoY and +17% sequentially, alongside $472M in Q2 earnings (nearly double YoY) as operating margins expand. Management flagged sizable commercial runway (only ~20% of gMG patients on novel biologics) and expects multiple pivotal readouts from 1H 2027 through 2H 2027, including potential launches tied to empasiprubart and Vyvgart franchise expansion. Wall Street is constructive: 20 of 23 analysts rate the stock a “buy/strong buy,” with a 12-month price target implying ~14% upside, despite shares trading at 37.5x forward earnings.

Analysis

ARGX is becoming less of a single-product story and more of a platform compounding story, which matters because the market usually pays up most for biotechs when each new indication lowers the perceived probability of the next one. The key second-order effect is not just incremental sales; it is that each clean readout should extend the terminal value duration and make the current multiple easier to defend, even if the stock has already rerated. That said, the valuation leaves little room for execution slippage, so the next leg higher likely requires a sequence of de-risking events rather than one good print.

The competitive dynamic is unfavorable for smaller autoimmune players trying to build around a single indication, because ARGX is building a branded ecosystem with commercial scale, trial cadence, and physician familiarity. For HALO, stronger Hytrulo adoption is a hidden positive, but that benefit is more linear and less asymmetric than the equity story in ARGX; it looks like a steadier royalty stream rather than a growth re-rating catalyst. If ARGX continues to take share in biologic-naive patients, the loser is the slower-adoption class of autoimmune therapies that rely on broader prescriber comfort and slower reimbursement cycles.

The real risk is timing mismatch: the stock can move on anticipation now, but the material re-rating catalysts are stretched across the next 12-18 months. Any dilution to the thesis would likely come from a single underwhelming phase 3 readout, slower-than-expected penetration in gMG/CIDP, or evidence that payer friction caps uptake in earlier-line patients. Conversely, if management starts quantifying a clearer funnel from current penetration to 2027 revenue, the market could still expand the forward multiple despite the already premium valuation.

The consensus appears to be underweighting how much optionality sits in the pipeline, but possibly overestimating how quickly that optionality converts into free cash flow. In biotech, "multiple pivotal results through 2027" is supportive only if capital markets remain open and investors are willing to underwrite a longer-duration growth curve; if risk appetite fades, ARGX can de-rate even while fundamentals improve. The cleanest takeaway is that the name is still fundamentally strong, but it has shifted from a simple quality-growth buy to a catalyst-trading vehicle.

Key Decisions for Investors

• Long ARGX into catalyst windows, but prefer staged entry on any 5-8% pullback rather than chasing strength; reward is a continued premium-multiple defense into the Q4 2026/MMN readout, while the key risk is a single binary miss that could compress the forward P/E materially.
• Pair idea: long ARGX / short XBI for the next 3-6 months if you want single-name alpha against biotech factor risk; thesis is that ARGX can outperform even if the sector struggles, because its readout cadence is more visible than the average biotech basket.
• Add HALO as a lower-volatility second-order beneficiary if you want exposure to Hytrulo penetration without paying ARGX’s full growth multiple; upside is steadier royalty growth, but this is a slower-burn trade and not a substitute for ARGX's pipeline optionality.
• Treat Q4 2026 as the first major falsification point: if empasiprubart data disappoints, reduce ARGX immediately because the market will likely question the 'pipeline-in-a-product' narrative and re-rate the stock lower despite current operating strength.
• Watch for any guidance language around patient penetration and reimbursement in 2027; if management can’t show acceleration in novel-biologic adoption, the stock may become range-bound and the premium multiple will be harder to sustain.